The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Study Identifier:
AP-0102
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
ApcinteX Ltd
Collaborator:
Centessa Pharmaceuticals plc
Study Contact Information:
N/A
Unmapped

Study Details

Medical Condition
  • Hemophilia A
  • Hemophilia B
Study Drug
  • Drug: SerpinPC
Date
Jul 2023 - Nov 2024
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Male
Age: 12 - 65 Years years
Requirements Information

Protocol Summary

This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

Trial Locations

Location
Status
Location
University of Colorado School of Medicine
Aurora, Colorado, United States, 80045-7202
Status
N/A
Location
University of South Florida
Tampa, Florida, United States, 33612
Status
N/A
Location
Indiana Hemophilia and Thrombosis Center, Inc.
Indianapolis, Indiana, United States, 46260
Status
N/A
Location
University of Iowa Healthcare
Iowa City, Iowa, United States, 52246
Status
N/A
Location
University of Michigan
Ann Arbor, Michigan, United States, 48109
Status
N/A
Location
University of Minnesota Medical Center
Minneapolis, Minnesota, United States, 55455
Status
N/A